Tirzepatide is another GLP-1 agonist that also targets glucose-dependent insulinotropic polypeptide (GIP), enhancing its effectiveness in weight loss and blood sugar control
These effects were subsequently managed through slower absorption kinetics, extended dosing intervals, and careful titration, allowing therapeutic benefit to outweigh adverse events ( 5.1 Peptide YY and the misinterpretation of early tolerability signals Peptide YY (PYY) is secreted postprandially by enteroendocrine L cells and functions as a satiety hormone by activating Y2 receptors in the hypothalamus and brainstem, where it inhibits neuropeptide Ymediated orexigenic signaling ( However, subsequent clinical trials reported high rates of nausea and vomiting, leading to the perception that PYY-based therapies were intrinsically intolerable
2) Do not take if you are pregnant or breastfeeding
Based on six clinical trials involving approximately 900 participants, AOD-9604 has demonstrated an excellent safety profile indistinguishable from placebo
Reduced cancer incidence, longer survival, and fewer metastases were also seen with GLP-1 use in patients with endometrial, bladder and prostate cancers, as well as in those with small intestine neoplasms and blood cancers, multiple studies found
Injectable glutathione works because it bypasses the gut entirely
